NICE backs rimonabant for overweight patients

NICE has issued final guidance on the use of rimonabant for the treatment of overweight and obese patients.

The guidance recommends that rimonabant be used as an addition to diet and exercise for adults who are obese or overweight and who have had an inadequate response to orlistat and sibutramine.

Treatment with rimonabant should be continued beyond six months only if the patient has lost at least 5 per cent of their initial body weight since using the drug.

But rimonabant treatment should be stopped if the patient returns to their pre-treatment weight, and treatment should not be continued for longer than two years without a formal clinical assessment.

Andrew Dillon, executive lead for the NICE obesity guidelines, said: ‘This is good news for patients for whom orlistat and sibutramine are not effective.’

sanjay.tanday@haymarket.com

NICE website

Comment below and tell us what you think

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus